echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Anti-HER2 dual-specific antibody KN026 and Aibo new combined drug treatment program was approved clinically

    Anti-HER2 dual-specific antibody KN026 and Aibo new combined drug treatment program was approved clinically

    • Last Update: 2021-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At present, the international treatment of HER2-positive breast cancer in the large molecule targeted drugs have curto-bead monoanti and pato-pearl monoanti.
    almost all HER2-positive metastasis breast cancer patients develop the disease.
    preclinical studies have shown that cell cycle protein-dependent kinase 4 and 6 (CDK4/6) inhibitors show increased HER2 activity and increased sensitivity to HER2 kinase inhibitors or antiHER2 antibodies.
    combination therapy of standard HER2 targeted therapy with CDK4/6 inhibitors can improve the outcome of treatment in patients with hormone-positive (HR-plus)/HER2-positive metastases breast cancer.
    KN026 is an anti-HER2 dual-specific antibody developed by CorningErry, which binds to both non-overlapping tables of HER2, blocking the dual HER2 signal.
    phase I./II. clinical trials have shown that KN026 has good tolerance and safety, and has significant anti-tumor activity in HER2-positive breast cancer patients who progress after multi-line anti-HER2 treatment.
    March 2020, CorningEry signed a clinical supply agreement with Pfizer to advance the KN026's joint drug trial with the oral CDK4/6 inhibitor Aibo new ® (Pybersili).
    The joint drug will begin with a multi-center, open-label phase I.b/II clinical study to assess the effectiveness, safety and tolerance of KN026 combined pyridoxie in the treatment of local late-stage non-removable or metastasis HER2-positive breast cancer patients.
    by Fudan University Affiliated Oncology Hospital Professor Wu Wei as the lead researcher, the main endpoints of the study are dose-limiting toxicity (DLT) and objective mitigation rate (ORR).
    trial as a potential chemotherapy-free option will give new hope to HER2-positive breast cancer patients.
    this time, based on a large number of previous research work, KN026 liquid large-size dosage form has also been approved for clinical use.
    than previous freeze-dried preparations, liquid preparations reduce process steps and facilitate clinical use.
    About KN026 KN026 is Corning Jerry's anti-HER2 dual-specific antibody developed with independent intellectual property Fc isoid platform technology (CRIB), which can bind to two non-overlapping tables of HER2 at the same time, resulting in double HER2 signal blocking, to achieve the effects of cratural bead monoantitor and patoju single anti-monosovironment and association, such as showing higher affinity, as well as excellent tumor inhibition in HER2-positive tumor cells.
    , KN026 also inhibited her2 medium- and low-expression tumors and crater-beaded single resistant cell strains.
    KN026 has been approved by China's State Drug Administration (NMPA) and the U.S. Food and Drug Administration (FDA) in 2018, and is currently conducting a number of Phase I./II. clinical trials in China, as well as advancing Phase I. clinical trials in the United States.
    phase I clinical trial results showed that KN026 had good tolerance and safety, and showed significant anti-tumor activity in HER2-positive breast cancer patients who progressed after multi-line anti-HER2 treatment.
    references: s1, W., et al., Cancer statistics in China, 2015. CA Cancer J Clin, 2016. 66(2): p. 115-32. [2] Iqbal, N. and N. Iqbal, Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int, 2014. 2014: p. 852748. [3] Qiu, M.Z., et al., HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. Int J Cancer, 2014. 134(10): p. 2468-77. [4] Kai Zhang, Ruoxi Hong, Lee Kaping, et al. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. Cancer Lett. 2019 Apr 10; 447:130-140. [5] Sara M Tolaney , Andrew M Wardley, Stefania Zambelli, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol .2020 Jun; 21(6):763-775. Source: Corning Jerry Note: The original text has been cut
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.